Institute of Science Tokyo · Institute for Advanced Studies · 准教授

Research keywords創薬化学・ケミカルバイオロジー・ペプチド・有機合成

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Tsuji K, Bai K, Huang X, Tamamura H. Affinity enhancement of polo-like kinase 1 polo-box domain-binding peptides by N-methylation and lipidation. Organic & biomolecular chemistry. 2026.03; 24 (14): 3031-3039. ( PubMed , DOI )2026
• Tsuji K, Miura Y, Kuwata T, Matsuzaki R, Kobayakawa T, Matsumoto K, Ito Y, Yoshiya T, Matsushita S, Tamamura H. CD4 Mimic-Neutralizing Antibody Conjugates Synthesized by Site-Specific Modification Methods as HIV-1 Entry Inhibitors. ChemMedChem. 2026.02; 21 (3): e202500820. ( PubMed , DOI )2026
• Tsuji K, Huang X, Miyamoto M, Sukegawa S, Yokoo H, Takeuchi H, Demizu Y, Tamamura H. Application of HIV-1 viral protein R-derived-peptides as new E3 ligase-binding components of BRD4 degraders. RSC chemical biology. 2026.01; 7 (1): 136-143. ( PubMed , DOI )2026
• Tsuji K. [Development of Mid-size Bivalent Inhibitors Targeting a Cancer-related Kinase]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. 2025; 145 (10): 815-821. ( PubMed , DOI )2025

• ケミカルノックダウンを用いたHIV潜伏感染細胞再活性化機構の解明
• 「 共有結合型キナーゼ結合性リガンドを有する高親和性二価型Plk1阻害剤の創製 」 ― がん関連タンパク質Plk1のより深い理解を目指して ―
• Expanding the arsenal of drugs against COVID-19
• 「SARS-CoV-2のメインプロテアーゼに対する高活性かつ生体内安定型阻害剤の創製」 ― 新型コロナウイルスに対する新たな阻害剤 ―

• Official profile